Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

Stanley B Cohen,1,&ast; Mariah Z Leach2,&ast; 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; 2Mamas Facing Forward, Louisville, Colorado, USA&ast;These authors contributed equally to this workCorrespondence: Stanley B Cohen, Email s...

Full description

Bibliographic Details
Main Authors:	Cohen SB, Leach MZ
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-10-01
Series:	Open Access Rheumatology: Research and Reviews
Subjects:	biosimilars interchangeability rheumatoid arthritis
Online Access:	https://www.dovepress.com/biosimilars-for-rheumatoid-arthritis-riding-the-2023-wave-podcast-peer-reviewed-fulltext-article-OARRR

Similar Items

The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study)
by: M. A. Korolev, et al.
Published: (2021-01-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases
by: Horatiu Popoviciu, et al.
Published: (2023-09-01)

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
by: Josef S. Smolen, et al.
Published: (2020-08-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
by: Krzysztof Bonek, et al.
Published: (2021-02-01)

Dynamics of the level of calprotectin in patients with rheumatoid arthritis during rituximab biosimilar (Acellbia “Biocad”) therapy
by: A. S. Avdeeva, et al.
Published: (2021-09-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-01-01)

IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
by: Rui Hu, et al.
Published: (2023-02-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

The use of biosimilars as a new approach to the treatment of rheumatoid arthritis
by: N. V. Chichasova, et al.
Published: (2021-08-01)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
by: Claudiu Costinel Popescu, et al.
Published: (2022-12-01)

Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)
by: A. S. Avdeeva, et al.
Published: (2019-03-01)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022-12-01)

A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
by: Ahmadreza Jamshidi, et al.
Published: (2017-07-01)

Perception toward Biosimilars and Nonmedical Switching: A Cross-sectional Survey among Arab Rheumatologists
by: Mohammed A. Omair, et al.
Published: (2020-08-01)

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY)
by: E. L. Nasonov, et al.
Published: (2016-12-01)

The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis
by: A S Avdeeva, et al.
Published: (2019-05-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

An Empirical Analysis of the Perceived Challenges and Benefits of Introducing Biosimilars in Bangladesh: A Paradigm Shift
by: Eva Rahman Kabir, et al.
Published: (2018-09-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

Cost-effectiveness Analysis of Reference Infliximab (Remicade) Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumatoid Arthritis (Conference Paper )#
by: Hasan Raid Fadhil, et al.
Published: (2023-02-01)

Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging
by: Liese Barbier, et al.
Published: (2022-03-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
by: Manoela Manova, et al.
Published: (2018-09-01)

An overview of biosimilars for cancer, diabetes mellitus, rheumatoid arthritis and other immune-mediated diseases approved between 2016 and 2021
by: Sivakumar Priyarega, et al.
Published: (2022-01-01)

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
by: Min-Chan Park, et al.
Published: (2019-05-01)

Biosimilars: New guns for the treatment of rheumatological patients?
by: Daniela Marotto, et al.
Published: (2019-05-01)

Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists
by: Shakeel S, et al.
Published: (2020-11-01)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
by: Stanley B. Cohen, et al.
Published: (2018-07-01)

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare
by: Filipa Mascarenhas-Melo, et al.
Published: (2024-02-01)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
by: Roy M. Fleischmann, et al.
Published: (2021-09-01)

A practical guide about biosimilar data for health care providers treating inflammatory diseases
by: Markenson J, et al.
Published: (2017-02-01)

Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar – Preliminary report
by: Benjamín Reyes-Beltrán, et al.
Published: (2017-01-01)

The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018-10-01)